Abstract: The invention provides methods, compositions, and medical kits for treating lymphoma using 6,8-bis-benzylthio-octanoic acid or a pharmaceutically acceptable salt thereof, optionally in combination with a second therapeutic agent.

Abstract: The invention provides methods and compositions for treating cancer by administering to a patient in need thereof a therapeutically effective amount of 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor.

Abstract: The invention provides methods and compositions for treating a disease or disorder by orally administering to a patient in need thereof 6,8-bis-benzylthio-octanoic acid or a pharmaceutically acceptable salt thereof, optionally in combination with a second therapeutic agent.

Abstract: The invention provides methods, compositions, and medical kits for treating acute myeloid leukemia using devimistat in combination with cytarabine and mitoxantrone.

Abstract: Compositions and methods are disclosed for identifying patients for treatment of hematological malignancy.

Abstract: F10 is an oligonucleotide based on the thymidylate synthase (TS) inhibitory 5-fluorouracil (5-FU) metabolite, 5-fluoro-2?-deoxyuridine-5?-O-monophosphate. The activity of F10 against preclinical ALL models was determined. F10 treatment resulted in robust induction of apoptosis that could not be equaled by 100 fold more 5-FU. F10 was more potent than Ara-C and doxorubicin against a panel of murine and human ALL cells with an average IC50 value of 1.48 nM (range 0.07 to 5.4 nM). F10 was more than 1000 times more potent than 5-FU. In vivo, F10 treatment resulted in a significant increase in survival in 2 separate syngeneic ALL mouse models and 3 separate xenograft models. F10 also protected mice from leukemia-induced weight loss. In ALL cells made resistant to Ara-C F10 remained highly active in vitro and in vivo. Using labeled F10, it was determined that uptake by the ALL cell lines DG75 and SUP-B15 was rapid and had a profound temperature dependence.

Abstract: The present invention relates to active compounds for treating acute myelogenous leukemia (AML) in a subject in need thereof and methods of treating AML carried out by administering the subject an active compound in an amount effective to treat the leukemia. The active compound comprises a 10-mer oligonucleotide covalently linked via 3? to 5? phosphodiester linkages of 5-fluorodeoxyuridine, FdUMP[10], or a pharmaceutically acceptable salt thereof.

Abstract: A method of treating acute myelogenous leukemia (AML) in a subject in need thereof is carried out by administering the subject an active compound in an amount effective to treat the leukemia. The active compound comprises FdUMP[10] or a pharmaceutically acceptable salt thereof.